A combination of immunotherapy and chemotherapy (such as atezolizumab plus nab-paclitaxel) was shown to improve the progression-free survival (PFS) and overall survival rate in metastatic TNBC (11, 41), and application of a vaccine against the GBM-specific WT1 peptide significantly increased PFS and overall survival in patients by inducing production of anti-WT1 antibodies and T cell responses (49). The gene discussed is WT1; the disease is glioblastoma.